Popular on TelAve
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- Jurllyshe Stacked Pants: A Perfect Addition Fall/Winter 2020 Wardrobe
- Ebony Doughboys Productions: The Gift of Courageous Hospitality
- Zurich Technology Solutions Partners with Facebook Connectivity to Build SuperCell
- Bid Ops Partners With Marcus Evans To Announce Optimal: The AI Conference for Procurement Teams
- Syxsense Confirms There is Zero SolarWinds® Orion® in its Environment and is Not a SolarWinds Customer
- Grammy nominated, Multiplatinum Producer "Khao" partners with tech company to create Christmas album for families to engage amid Covid-19
- Global Issuing & Acquiring Processor Digital Cash Processing Names Ram Chary CEO and Chairman of the Board
- PicPocket-Labs, Inc. adds to Executive team; appoints Michael Petersen as CTO
- RiseUP TV! Why COVID is NOT slowing us down!
Similar on TelAve
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- Be an Example, Get the Covid Shot
- Why Medical Massage Means More Guarantees of Pain Relief for Massage Patients in Los Angeles
- Thomas Mitchiner Law--Unraveling the complexities of Employment Law
- Green Health Eugene and COVID Information
- Perfect Body Laser and Aesthetics® Now Has Sunetics, The First FDA-Approved Low-Level Laser To Treat 95% Of All Hair Loss
- Lee Enterprises Consulting Named Top Bioeconomy Consulting Group
- Mending Kids is Holding its Eighth Hometown Mission in Long Beach, CA
- DMS Prioritizes Health & Wellbeing Of Employees
- Facebook Sued by FormerFedsGroup.Com Over Pandemic Censorship and Suppression of Life Saving Health Information
Sedia Biosciences Corporation announces expansion and move to new research and manufacturing facility in Beaverton, Oregon, USA
TelAve News/10636020
Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide
BEAVERTON, Ore. - TelAve -- Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon. The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities. Equipped with multiple state of the art, environmentally controlled production, quality and research laboratories, high throughput production equipment, and expanded warehouse capacity, the facility is also designed to accommodate the "new normal" of business in a pandemic challenged environment. The new facility will have a much needed immediate impact on production capacity of Sedia's products, now being used in partnership with the U.S. Centers for Disease Control and Prevention (CDC, www.cdc.gov), PEPFAR (President's Emergency Plan for AIDS Relief, www.pepfar.gov), and other NGOs and stakeholders working with Sedia.
More on TelAve News
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on TelAve News
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
More on TelAve News
- Be an Example, Get the Covid Shot
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
- Thiel College names Terry Eddy to Board of Trustees
- "Diamond Fuji" to be Seen from TOKYO SKYTREE in February
- Texpak Offers Environmentally-Friendly Ecotach™ Fasteners to Address Sustainability Needs
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on TelAve News
- Covid-19 Resulted In A 69% Increase In Customer Service Call Volumes For Resultscx Retail Clients
- Morningstar names Quantified STF Fund top-performing tactical-allocation fund in 2020
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- SHELTER, New Works by Artists Byron Keith Byrd, Stefani Byrd, and Fenix Gallery Collective, January 20–February 24, 2021
- AI.Reverie Awarded $950 Million IDIQ Contract for U.S. Air Force Advanced Battle Management System (ABMS)
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
Source: Sedia Biosciences Corporation
0 Comments
Latest on TelAve News
- Why Medical Massage Means More Guarantees of Pain Relief for Massage Patients in Los Angeles
- Low-Cost Colour Printing with the Epson WorkForce WF-C879R High Speed Office Inkjet Printer
- BitRouter Announces 3pi ATSC 3.0 Receiver for Automotive and Distance Learning Applications
- Love vs. Design Launches With Instantly Customizable Peel And Stick Wallpapers For Your Home
- Latin Pop/Rock group Al Cielo - First Time Meeting In Person
- Play FLIP FORWARD by Autonomous & You Might Find Yourself $2000 Richer!
- Spice Resto-Lounge Welcomes Actor & Entertainer Alex Castro As New Entertainment Director
- An Irish-US Partnership of Note
- NEAT Elite Glass Now Available Worldwide
- Thomas Mitchiner Law--Unraveling the complexities of Employment Law
- Credo Capital Partners joins hands with Scienaptic for sharper credit assessment of financial assets
- Green Health Eugene and COVID Information
- AvoLimo LLC-Colorado and COVID-19
- Rueben Wood Launches Esport & Game Development Company!
- Perfect Body Laser and Aesthetics® Now Has Sunetics, The First FDA-Approved Low-Level Laser To Treat 95% Of All Hair Loss
- Post Family Pledges $50K to the Naval Aviation Museum Foundation
- Huge Increase in U.S. Carjackings Results in an 800% Increase in Armoring
- Reduce Your Stress While Getting The Best
- Lee Enterprises Consulting Named Top Bioeconomy Consulting Group
- GDS21 Launches Global Hearts Local Business Training Series